Correlation between paraoxonase-1 arylesterase activities and clopidogrel drug in patients with coronary artery disease
Keywords:
coronary artery disease, paraoxonase 1, clopidogrel, malondialdehyde, lipid peroxidationAbstract
Background: Coronary artery disease (CAD) is one of the leading causes of death worldwide. Clopidogrel, antiplatelet drug, has been widely used for management of CAD. Arylesterase, the activity of Paraoxonase-1 (PON-1), is mainly contributed in the biotransformation of clopidogrel to its active thiol form. The purpose of this study was to investigate the effect of receiving clopidogrel drug on the arylesterase activities in CAD patients. The effect of receiving clopidogrel drug on the antioxidant activity of arylesterase was also monitored by determination of malondialdehyde (MDA) level. Methods: One hundred CAD patients, who were followed-up for 5 days after reciving clopidogrel, and 50 healthy volunteers were included in our study. The activities of arylesterase using two (phenyl acetate and p-nitrophenyl acetate) substrates, lipid profile, MDA, and total protein concentration (Tp) were determined spectrophotometrically. Results: PON-1 arylesterase activities, HDL-C, and Tp were significantly decreased (P<0.0001) in patients with CAD before receiving clopidogrel drug (CAD-pre-Clp) compared to baseline (non-CAD) and the levels of these parameters were returned to baseline (P>0.05) after 5 days of receiving clopidogrel (CAD-post-Clp).
Downloads
References
Al-Ani AW, Fadel SS. Arlyesterase activity of Paraoxonase-1 enzyme in Iraqi patients with β-thalassemia minor.
Ancrenaz V, Desmeules J, James R, Fontana P, Reny JL, Dayer P, Daali Y. The paraoxonase‐1 pathway is not a major bioactivation pathway of clopidogrel in vitro. British journal of pharmacology. 2012; 166(8):2362-2370
Brites F, Martin M, Guillas I, Kontush A. Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA clinical. 2017; 8:66-77
Dönmezdil N, Çevik MU, Özdemir HH, Taşin M. Investigation of PON1 activity and MDA levels in patients with epilepsy not receiving antiepileptic treatment. Neuropsychiatric Disease and Treatment. 2016; 12:1013
Dubois-Deruy E, Peugnet V, Turkieh A, Pinet F. Oxidative stress in cardiovascular diseases. Antioxidants. 2020; 9(9):864
Godbole C, Thaker S, Kerkar P, Nadkar M, Gogtay N, Thatte U. Association of PON1 gene polymorphisms and enzymatic activity with risk of coronary artery disease. Future Cardiology. 2020; 17(1):119-126
Gur M, Aslan M, Yildiz A, Demirbag R, Yilmaz R, Selek S, Erel O, Ozdogru I. Paraoxonase and arylesterase activities in coronary artery disease. European journal of clinical investigation. 2006; 36(11):779-787
Hasan HR, Numan AW. BIOCHEMICAL STUDY ON SUPEROXIDE DISMUTASE ENZYME IN PATIENTS WITH DIFFERENT BRAIN TUMORS.
Hasan HR, Numan AW. Extracellular superoxide dismutase changes in patients with different brain tumors. Iraqi Journal of Science. 2009; 50(1):1-7
Hussain NK, Rzoqi SS, Numan AW, Ali DT. A comparative study of fructose, zinc and copper levels in seminal plasma in fertile and infertile men. Iraqi J Med Sci. 2000; 48
Jaouad L, de Guise C, Berrougui H, Cloutier M, Isabelle M, Fulop T, Payette H, Khalil A. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydyl groups. Atherosclerosis. 2006; 185(1):191-200
Jasim RH, Numan AW, Hasan SM. Evaluation of oxidative stress and liver function parameters in the sera samples of Kufa cement factory workers. Journal of Kufa for Chemical Science. 2012; 6(5):40-50
Kadhum BS, Al-Shammaree SAW. Association of Iron Status in Follicular Fluid with Pregnancy Outcomes in Infertile Women Undergoing IVF/ICSI. Iraqi Journal of Science. 2021:1779-1786
Kexin W, Yaodong D, Wen G, Rui W, Jiaxin Y, Xiaoli L, Hua S, Hailong G. Association of increased remnant cholesterol and the risk of coronary artery disease: a retrospective study. Frontiers in cardiovascular medicine. 2021; 8
Kumar R, Saini V, Kaur C, Isser H, Tyagi N, Sahoo S. Association between PON1 rs662 gene polymorphism and serum paraoxonase1 level in coronary artery disease patients in Northern India. Egyptian Journal of Medical Human Genetics. 2021; 22(1):1-8
Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nature Reviews Cardiology. 2011; 8(4):222-232
Numan AW. Study on total peroxidase enzymes activities and some trace elements in patients with breast tumors. Iraqi Journal of Biotechnology. 2010; 9(4):828-837
Rye K-A, Barter PJ. Cardioprotective functions of HDLs1. Journal of lipid research. 2014; 55(2):168-179
Shen H, Li M, Wang B, Lai IK, Robertson LW, Ludewig G. Dietary antioxidants (selenium and N-acetylcysteine) modulate paraoxonase 1 (PON1) in PCB 126-exposed rats. Environmental Science and Pollution Research. 2014; 21(10):6384-6399
Stadler JT, Marsche G. Obesity-related changes in high-density lipoprotein metabolism and function. International Journal of Molecular Sciences. 2020; 21(23):8985
Stadler JT, Wadsack C, Marsche G. Fetal High-Density Lipoproteins: Current Knowledge on Particle Metabolism, Composition and Function in Health and Disease. Biomedicines. 2021; 9(4):349
Talebi S, Paknahad Z, Hashemi M, Hasanzadeh A. Antioxidant status and risk of coronary artery disease. Nutrition & Food Science. 2018
Tselepis A, Tsoumani M, Kalantzi K, Dimitriou A, Tellis C, Goudevenos I. Influence of high‐density lipoprotein and paraoxonase‐1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. Journal of Thrombosis and Haemostasis. 2011; 9(12):2371-2378
Tvarijonaviciute A, Tecles F, Caldin M, Tasca S, Cerón J. Validation of spectrophotometric assays for serum paraoxonase type-1 measurement in dogs. American journal of veterinary research. 2012; 73(1):34-41
Varadhan S, Venkatachalam R, Perumal S, Ayyamkulamkara S. Evaluation of Oxidative Stress Parameters and Antioxidant Status in Coronary Artery Disease Patients. Archives of Razi Institute. 2022; 77(2):853-859
Weitner T, Inić S, Jablan J, Gabričević M, Domijan A-M. Spectrophotometric determination of malondialdehyde in urine suitable for epidemiological studies. Croatica Chemica Acta. 2016; 89(1):133-139
Wysocka A, Cybulski M, Wysokiński AP, Berbeć H, Stążka J, Zapolski T. Paraoxonase 1 activity, polymorphism and atherosclerosis risk factors in patients undergoing coronary artery surgery. Journal of Clinical Medicine. 2019; 8(4):441
Zuin M, Trentini A, Marsillach J, D’Amuri A, Bosi C, Roncon L, Passaro A, Zuliani G, Mackness M, Cervellati C. Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis. Disease markers. 2022; 2022
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
